Cart summary

You have no items in your shopping cart.

    Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [6G9]

    Catalog Number: orb1274615

    DispatchUsually dispatched within 5-10 working days
    $ 1,166.00
    Catalog Numberorb1274615
    CategoryAntibodies
    DescriptionRecombinant SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [6G9]
    Species/HostHuman
    ClonalityRecombinant
    Clone Number6G9
    Tested applicationsELISA
    ReactivityVirus
    IsotypeHuman IgG1
    Immunogenfull length recombinant Nucleocapsid Protein
    Concentration5.0 mg/ml (+/- 10 %)
    Dilution rangeImmunoreactivity: 80-120 % compared to the reference sample in an ELISA test.
    Form/AppearanceLiquid
    ConjugationUnconjugated
    TargetN
    UniProt IDP0DTC9
    NCBIQHD43423
    Storage24 months from manufacturing at < -20 °C; 1 month, 2 to 8 °C under sterile conditions.
    Buffer/PreservativesPBS, pH 7.4
    Alternative namesSARS-CoV-2 (COVID-19) Nucleocapsid Antibody: Sever
    Read more...
    NoteFor research use only
    Application notesImmunoreactivity: 80-120 % compared to the reference sample in an ELISA test.
    Expiration Date12 months from date of receipt.
    Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [6G9]

    Immobilized 2019-nCoV Nucleocapsid Protein (Cat#orb1228242) at 5.0μg/ml (100μL/well) can bind 2019-nCoV NP Antibody (6G9), the EC50 for this effect is 5-30ng/ml.

    Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [6G9]

    Loaded 2019-nCoV Nucleocapsid Protein-His (Cat#orb1228242) on HIS1K Biosensor, can bind 2019-nCoV NP Antibody (6G9) (Cat#orb1274615) with an affinity constant of 1.15 nM as determined in BLI assay.

    Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [6G9]

    Please note that pair recommendations are based on results obtained by our laboratory. Equally good results may be obtained using other pairs and therefore these recommendations are only indicative.

    Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [6G9]

    Freeze-thaw stability is tested by repeated freeze-thaw cycles. The result showed that product bioactivity is no significant differences after freeze-thawing 10 times.

    Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [6G9]

    Stability is confirmed by binding ability with 2019-nCoV Nucleocapsid Protein (Cat#orb1228242). The result showed that product bioactivity is no significant differences among these samples.

    Submit a review

    Filter by Rating

      • Star
      • Star
      • Star
      • Star
      • Star
      • 5 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 4 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 3 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 2 stars
      • Star
      • Star
      • Star
      • Star
      • Star
      • 1 stars